ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.652,67
0,44%
S&P 500
5.352,96
-0,02%
Dow Jones
38.886,17
0,20%
Euro vs US Dollar
1,08942
0,03%
Bitcoin
71.216,73
0,64%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Europa
  5. EU
  6. Pharming Group NV (PHARM)

  7. Pharming Group NV (PHARM) News

PHARM

Pharming Group NV (PHARM)

Pharming Group NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:EU:PHARM
DatumZeitQuelleÜberschriftSymbolFirma
03/06/202408h00GlobeNewswire Inc.Pharming Group to participate in June investor conferencesEU:PHARMPharming Group NV
03/06/202408h00GlobeNewswire Inc.Pharming Group to participate in June investor conferencesEU:PHARMPharming Group NV
30/05/202422h44GlobeNewswire Inc.Pharming Group provides update on ongoing regulatory review of leniolisib for the treatment of APDS in the European UnionEU:PHARMPharming Group NV
21/05/202417h30GlobeNewswire Inc.Pharming Group reports on results of the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
21/05/202417h30GlobeNewswire Inc.Pharming Group reports on results of the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
20/05/202408h00GlobeNewswire Inc.Pharming Group to participate in May investor conferenceEU:PHARMPharming Group NV
20/05/202408h00GlobeNewswire Inc.Pharming Group to participate in May investor conferenceEU:PHARMPharming Group NV
15/05/202407h00GlobeNewswire Inc.Pharming Group announces the early redemption of the remaining outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/05/202407h00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
08/05/202407h00GlobeNewswire Inc.Pharming Group reports first quarter 2024 financial results and provides business updateEU:PHARMPharming Group NV
24/04/202408h00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202407h00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
24/04/202407h00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202418h43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202415h04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202408h00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202407h00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
08/04/202407h00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202408h30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202407h00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202408h00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
03/04/202408h00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202407h00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202408h00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
29/02/202408h00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202408h00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/02/202408h00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202407h00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
08/01/202407h00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202307h00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
 Showing the most relevant articles for your search:EU:PHARM

Kürzlich von Ihnen besucht

USOTC
KTYCF
Kits Eyecare (PK)
LSE
15ZH
Anglo Am. 19
BIT
P1Y0N6
NLBNPIT1Y0N6 20351221 83...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten